GE HealthCare Technologies Inc. (GEHC) Stock Price & How to Invest

GE HealthCare is the medical technology business spun off from the former General Electric conglomerate as an independent company. It is one of the world's largest makers of medical imaging and diagnostic equipment. Its product portfolio spans MRI, CT, X-ray, ultrasound, and molecular imaging systems, plus contrast agents and radiopharmaceuticals used in scans, patient monitoring devices, and a growing suite of healthcare software and AI tools that help clinicians interpret images and manage care. GE HealthCare makes money by selling these large imaging systems to hospitals and clinics, and importantly through recurring revenue from service contracts, maintenance, software, and consumables like contrast media. With a large installed base of equipment worldwide, the company benefits from steady demand for diagnostics, an aging global population, and the growing role of AI in radiology. Headquartered in Chicago, it serves healthcare providers across developed and emerging markets and competes among the top global medical imaging vendors.

GE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases. It faces intense competition from Siemens Healthineers, Philips, and others, and pricing pressure in mature imaging categories. Supply chain disruptions and component shortages can affect deliveries. As a recently independent company, it carries debt from the spinoff and must execute on its own strategy. Regulatory approval, reimbursement changes, and product recalls are risks in medical devices. Currency swings affect its global revenue. Margins in hardware can be modest, and growth depends on successfully expanding higher-margin software, services, and contrast media against capable, well-resourced competitors.

18 analysts publish price targets on GEHC, averaging $79.33 against a $71.19 price as of July 2026, or +11.4%. The published targets run from $65.00 to $98.00, a moderate spread, and the ratings split 14 buy, 5 hold, 0 sell. Over the last six months there have been 0 raises and 9 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GEHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on GE HealthCare Technologies Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Large installed base and recurring revenue. GE HealthCare has a vast installed base of imaging systems worldwide, generating recurring revenue from service contracts, maintenance, software, and consumables such as contrast agents. The most optimistic published target, $98.00, assumes this works close to its best case.

The case against. GE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases. The most pessimistic target, $65.00, is roughly what GEHC is worth if this bites instead.

Read the full bull and bear case on GEHC, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see GE HealthCare Technologies Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$19 to 21 billion
• Operating margin: ~mid teens percent
• Net income (TTM): ~$2 billion or more
• Recurring revenue mix: ~meaningful service and consumables
• Dividend yield: ~under 1%
• Free cash flow: ~steady
• Market cap: ~tens of billions

GE HealthCare is valued as a defensive medical technology company with a large installed base and recurring service and consumables revenue. Investors weigh steady diagnostics demand and AI-driven product upgrades against competition and hospital capital-spending cycles. The valuation reflects a stable healthcare franchise with moderate growth and the optionality of expanding software and higher-margin businesses.

Other names that sit close to GEHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get GEHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GEHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GEHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

GE HealthCare (GEHC) is a steady medical-imaging franchise whose recurring service and consumables revenue cushions hardware cyclicality, supported by aging-population diagnostics demand and AI-enabled imaging. In a portfolio it behaves as a defensive healthcare holding with moderate growth, carrying hospital capital-spending cycles and spinoff debt as its main risks.

Whether GEHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GEHC a buy or a sell?, and where the stock could go from here in the GEHC stock forecast.

For income investors, whether GEHC pays a dividend and how the payout looks is covered in does GEHC pay a dividend? And to weigh GEHC against a peer, read the full side-by-side comparisons: GEHC vs HNGE and GEHC vs BMY.